Individuals with a genetic predisposition to Alzheimer's disease show altered blood levels indicating damaged neuronal contacts as early as 11 years before the expected onset of dementia symptoms.

Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 /IGC Pharma ...

Alzheimer’s blood test ‘can accurately pick up early symptoms’ - Researchers found the blood test was 95% accurate in picking up people with the disease, with very few cases missed.

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection Provided by ACCESS Newswire Jul 10, 2025, 7:10:00 PM ...

ALZpath's proprietary pTau217 antibody enables highly sensitive and accurate blood-based detection of phosphorylated tau at position 217 (pTau217), a key Alzheimer's disease biomarker, supporting ...

A study involving more than 1,700 people from five hospitals in Barcelona, Sweden and Italy has validated the usefulness of a biomarker in blood to detect Alzheimer's disease in the clinical setting.